Q4 Earnings Forecast for Cingulate Issued By HC Wainwright

Cingulate Inc. (NASDAQ:CING) – Equities research analysts at HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for Cingulate in a note issued to investors on Thursday, January 30th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($1.05) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. HC Wainwright also issued estimates for Cingulate’s Q1 2025 earnings at ($1.05) EPS, Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.58) EPS and Q4 2025 earnings at ($0.56) EPS.

Cingulate (NASDAQ:CING) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.22) by $0.39.

Several other research analysts also recently weighed in on CING. Roth Mkm initiated coverage on shares of Cingulate in a research report on Friday, January 10th. They issued a “buy” rating and a $12.00 target price on the stock. Roth Capital upgraded shares of Cingulate to a “strong-buy” rating in a research report on Friday, January 10th. Finally, Maxim Group raised shares of Cingulate from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th.

Cingulate Stock Performance

Shares of Cingulate stock opened at $4.56 on Monday. The business has a fifty day simple moving average of $4.58 and a 200-day simple moving average of $4.65. Cingulate has a fifty-two week low of $1.80 and a fifty-two week high of $20.83.

Institutional Trading of Cingulate

A hedge fund recently raised its stake in Cingulate stock. AlphaMark Advisors LLC raised its holdings in Cingulate Inc. (NASDAQ:CING) by 50,000.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,010 shares of the company’s stock after buying an additional 5,000 shares during the quarter. AlphaMark Advisors LLC owned 0.16% of Cingulate worth $25,000 as of its most recent SEC filing. 41.31% of the stock is owned by institutional investors and hedge funds.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.